The companies will use Ymir's urine extracellular vesicle technology and OHSU's Proteomics Shared Resource to develop biomarkers for hepatocellular carcinoma.
Retraction Watch reports that Nature has added an editor's note to a paper describing the correction of a pathogenic mutation in human embryos.
OHSU researchers will use Biological Dynamics' NanoVerita and ExoVerita lab-on-a-chip systems to develop early cancer detection methods.
In Nature this week: CRISPR/Cas9 used to correct a disease-causing mutation in embryos, and more.
Researchers have used the gene-editing tool CRISPR/Cas9 to correct a mutation linked to hypertrophic cardiomyopathy in embryos.
Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.
The institute will join the NCI's Cancer Systems Biology Consortium, which is studying cancer initiation, progression, and metastasis.
OHSU was granted the rights to offer Biocept's Target Selector liquid biopsy testing services in Oregon as part of the deal.
The Seattle-based firm is working with Oregon Health & Science University researcher Lisa Coussens on a tool for studying the innate immune system in oncology.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.